Edward J. Dulac III

Edward J. Dulac III

Chief Financial OfficeratFate Therapeutics· In proxies 2022–2023

Pay in FY2023-11% from the year before · Fate Therapeutics stock -62.9% the same year

Edward J. Dulac III was paid $2.8M in FY2023 (Dec), down 11%. Fate Therapeutics stock fell 62.9% that year.

Pay$100 in the stock at the end of FY21 → $6
Pay is from the Summary Compensation Table of each Fate Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Fate TherapeuticsPublic company · 4 yr
    • Chief Financial Officer2022 – Present · 4 yrStock in role -96%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?